FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study Marie O’Farrell, Tim Heuer, Katharine Grimmer, Richard Crowley, Joanna Waszczuk, M

First Page		Document Content
Date: 2016-04-19 06:39:33 Clinical medicine Medicine Lung cancer Biology KRAS Non-small-cell lung carcinoma Biomarker Ras subfamily FASN Fatty acid synthase		FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study Marie O’Farrell, Tim Heuer, Katharine Grimmer, Richard Crowley, Joanna Waszczuk, M Add to Reading List Source URL: www.3vbio.com Download Document from Source Website File Size: 997,69 KB Share Document on Facebook

	InsFtute of Molecular Systems Biology   Accelerating 3D Protein Modeling Using Cloud Computing   Lars Malmström, Ruedi Aebersold – ETH Zürich, IMSB h?p://www.imsb.ethz.ch  Wibke Sud DocID: 1xW13 - View Document
	Biology 7-12 "DBEFNJD.BQ Post-Baccalaureate DocID: 1xVVF - View Document
	Biology 7-12, BS "DBEFNJD.BQ 5IF"DBEFNJD.BQTFSWFTBTBTVHHFTUFEDPVSTFTFRVFODFPOMZ4UVEFOUTBSFOPUMJNJUFEUPUIJTQMBOJUJTNFBOUUPCFVTFEBT DocID: 1xVB1 - View Document
	北京大学基础医学院院长论坛报告题目： How to Publish High Quality Articles 报告人： Mirella Bucci, Ph.D. Senior Editor of Nature Chemical Biology 时 DocID: 1xVbh - View Document
	Group Henzinger Software Systems Theory Systems Biology Group members DocID: 1xV3x - View Document